Table 1.

Demographic and clinical characteristics of the study population

	NCSF group (n = 55)	CSF group (n = 71)	p
Age	55.73 ± 11.93	55.85 ± 11.06	0.954
Male	34 (61.8%)	60 (84.5%)	0.004
BMI	26.29 ± 4.97	27.15 ± 3.41	0.251
Smoking history	24 (43.6%)	45 (63.4%)	0.021
Anti-platelet drugs	30 (54.5%)	36 (50.7%)	0.402
β-blockers	19 (34.5%)	23 (32.4%)	0.474
ACE inhibitors	6 (10.9%)	5 (7%)	0.326
ARBs	8 (14.5%)	10 (14.1%)	0.569
Statins	26 (47.3%)	31 (43.7%)	0.411
Hypertension	36 (65.5%)	42 (59.2%)	0.296
Diabetes	13 (23.6%)	10 (14.1%)	0.276
LVEF	64.11 ± 4.20	48.68 ± 4.16	0.264
LVEDd	48.44 ± 4.33	48.68 ± 4.16	0.753
CAE in LAD (%)	29 (52.7%)	52 (73.2%)	0.044
CAE in LCX (%)	14 (25.5%)	41 (57.7%)	0.001
CAE in RCA (%)	31 (56.4%)	52 (73.2%)	0.111
CAE in 1 vessel	33 (60%)	21 (29.6%)	0.001
CAE in 2 vessels	15 (27.3%)	26 (36.6%)	0.001
CAE in 3 vessels	7 (12.7%)	24 (33.8%)	0.001